The Inhibitor Study

The study drug is a potential new treatment for epileptic seizures associated with the genetic disorder tuberous sclerosis complex (TSC).

Already approved medication can cause side effects that are difficult to tolerate. Because of these issues, there is a need for a new treatment that causes fewer side effects and is still effective in controlling seizures.

The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.